Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIoannidis, P.en
dc.contributor.authorMahaira, L.en
dc.contributor.authorPapadopoulou, A.en
dc.contributor.authorTeixeira, M. R.en
dc.contributor.authorHeim, S.en
dc.contributor.authorAndersen, J. A.en
dc.contributor.authorEvangelou, E.en
dc.contributor.authorDafni, U.en
dc.contributor.authorPandis, N.en
dc.contributor.authorTrangas, T.en
dc.rightsDefault Licence-
dc.subjectAged, 80 and overen
dc.subjectBreast Neoplasms/genetics/*pathologyen
dc.subjectCell Differentiationen
dc.subjectChromosomes, Human, Pair 17/*genetics/ultrastructureen
dc.subjectChromosomes, Human, Pair 8/*genetics/ultrastructureen
dc.subject*Gene Amplificaen
dc.title8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomasen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.abstractThe coding region determinant binding protein (CRD-BP) was isolated by virtue of its high affinity to the c-myc mRNA coding region stability determinant and shown to shield this message from nucleolytic attack, prolonging its half-life. CRD-BP is normally expressed during fetal life but is also activated de novo in tumors. Considering that aberrant CRD-BP expression may represent an additional mechanism interfering with c-myc regulation, we screened 118 primary breast carcinomas for CRD-BP expression, 60 of which had also been analyzed by comparative genomic hybridization (CGH). Copy number gains encompassing 8q24, the chromosome band that contains the c-myc locus, were detected in 48.3% (29/60) of tumors, whereas gains involving band 17q21, which contains the CRD-BP locus, were observed in 18.3% (11/60) of tumors. CRD-BP expression was detected in 58.5% (69/118) of tumors, implying mechanisms of activation alternative to gene amplification. Altogether, some 75% of the tumors had alterations pertaining to c-myc since they either harbored 8q24 gains and/or expressed CRD-BP. Significant associations were detected between CRD-BP expression and the absence of estrogen receptors (p = 0.005) and between the presence of 8q24 gains and an increased number of genomic changes as measured by CGH (p = 0.0017). Tumors were divided into 4 groups according to CRD-BP expression and 8q24 gains. The odds for tumors having both characteristics to be classified as poorly differentiated (grade III vs. grade I and II) were 19.6 times the corresponding odds for tumors neither expressing CRD-BP nor harboring 8q24 gains. For tumors either harboring 8q24 gains only or expressing CRD-BP alone, the corresponding odds were 6.4 and 3, respectively.en
heal.journalNameInt J Canceren
heal.journalTypepeer reviewed-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Ioannidis-2003-8q24 Copy number gai.pdf120.12 kBAdobe PDFView/Open    Request a copy

This item is licensed under a Creative Commons License Creative Commons